Nutex Health Inc reports results for the quarter ended September 30 - Earnings Summary

Nutex Health

08/11/2024 21:02

* Nutex Health Inc  NUTX.OQ  reported a quarterly adjusted
loss of
$1.72​​ per share for the quarter ended September 30, lower than
the same quarter last year, when the company reported EPS of
$-1.50.  The mean expectation of two analysts for the quarter
was for a loss of 24 cents per share. Wall Street expected
results to range from -76 cents to 28 cents per share.
    * Revenue rose 25.6% to $78.79 million from a year ago;
analysts
expected $73.22 million. 
    * Nutex Health Inc's reported EPS for the quarter was a loss
of
$1.72​.
    * The company reported a quarterly loss of $8.79 million.
    * Nutex Health Inc shares had risen by 33.1% this
quarter and
gained 7.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 44.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Nutex Health Inc
is 45.00 
This summary was machine generated from LSEG data November 8 at
09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.24          -1.72          Missed
 Jun. 30 2024      -0.29          -0.07          Beat
 Mar. 31 2024      0.00           -0.60          Missed
 Dec. 31 2023      0.00           0.00           Met